# "Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

> **NCT01883297** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 3 (actual)

## Conditions studied

- Recurrent
- Platinum-resistant
- High Grade Serous Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer

## Interventions

- **BIOLOGICAL:** Re-stimulated tumor-infiltrating lymphocytes (TILs)
- **BIOLOGICAL:** Interleukin-2
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT01883297
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-01
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2024-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01883297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01883297, ""Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01883297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*